44 results about "Azythromycin" patented technology

The invention relates to a norhalal-enoxacin conjugate as well as a preparation method and application thereof. The norhalal-enoxacin conjugate comprises a norhalal-enoxacin coupling compound, or a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a pharmaceutically acceptable ester or a pharmaceutically acceptable solvate selected from the compound. Compared with enoxacin, kanamycin, streptomycin, lincomycin and azithromycin, the norharmann-enoxacin conjugate disclosed by the invention has a smaller MIC (Minimum Inhibitory Concentration) value, which shows that the norharmann-enoxacin conjugate has a better anti-staphylococcus aureus effect.

The invention discloses a bacteriostatic composition which comprises a synergist and a bacteriostatic agent, the synergist is ethyl phenylacetate or a derivative thereof, and the bacteriostatic agent is selected from hydrogen peroxide, beta-lactam antibiotics, macrolide antibiotics and aminoglycoside antibiotics. The synergist disclosed by the invention is wide in synergistic effect spectrum range, and has a remarkable synergistic bacteriostatic effect when being combined with hydrogen peroxide, amoxicillin, ampicillin, benzylpenicillin potassium, erythromycin, azithromycin and amikacin; the antibacterial effect is weak when the compound is independently used, but the virulence of staphylococcus aureus can be remarkably reduced, the formation of hemolysin, staphylococcus flavin, enterotoxin and a biofilm can be inhibited, and meanwhile, the selective pressure on bacteria is favorably reduced due to the relatively low antibacterial activity, so that the occurrence of drug resistance is delayed; the method is suitable for various application scenes such as food processing industry.

The invention discloses a method for preparing azithromycin by using a microchannel reactor. The method uses erythromycin as a starting material and prepares azithromycin through oximation, rearrangement, reduction and methylation reactions. During the oximation reaction, the contact time of the feed liquid in the microchannel reactor is very short, which greatly reduces the safety risk of the oximation reaction. The reduction reaction is carried out in the microchannel reactor, and neither explosive sodium (potassium) borohydride nor a high-pressure reactor is used, which reduces the safety risk. A tray layer of palladium carbon is laid on the reaction bed to achieve the hydrogenation target, while greatly improving the utilization efficiency of palladium carbon. In the rearrangement reaction, a milder leaving group, sodium 2-naphthalenesulfonate, is used to replace the existing leaving group. Water is used as a solvent and the reaction is carried out at room temperature. The method is green, safe, and has a high yield, and is suitable for industrial production.

This invention belongs to the field of pharmaceutical crystallization technology, specifically relating to a crystallization process for small-particle-size azithromycin fumarate with low solvent residue. In existing processes, azithromycin fumarate crystallizes in alcohol solvents, often resulting in residual ethanol. This invention provides a crystallization process for azithromycin fumarate by adding a portion of fumaric acid to azithromycin, then adding azithromycin fumarate seed crystals, inducing crystallization through ultrasonication, continuing to add fumaric acid, and then concentrating under reduced pressure for isothermal crystal growth. The azithromycin fumarate crystals prepared by this method have a particle size distribution range of 15-30 μm, and the ethanol residue is reduced to below 0.5%, allowing for direct use in pharmaceutical preparations without further purification. This results in a high-quality, economically viable active pharmaceutical ingredient.

To provide an ophthalmic agent and an ophthalmic antibacterial agent that contain azithromycin and are administered in specific doses and dosage regimens for specific indications.SOLUTION: The present invention relates to an ophthalmic agent that contains azithromycin and ophthalmologically acceptable additives to prevent or treat one or more of a patient's blepharitis, hordeolum, and lacrimal pouchitis or to prevent the progression of the disease, the ophthalmic agent being applied to the patient twice daily for 2 days and then once daily for 12 days in an appropriate quantity once. The invention also relates to an ophthalmic antibacterial agent.SELECTED DRAWING: None

The invention discloses a novel Fe-C-N-coated Au material and a preparation method and application thereof.According to the Fe-C-N-coated Au material, iron monatomic nano-enzyme Fe-C-N serves as a core, gold nanoparticles are loaded on the surface, the Fe-C-N nanoparticles and a HAuCl4 aqueous solution are stirred at low temperature, then an ice-cold NaBH4 solution is slowly added into a mixed solution, and the Fe-C-N-coated Au material is obtained after reaction and treatment. The novel Fe-C-N-coated Au material disclosed by the invention can be used for rapidly and sensitively detecting the azithromycin or macrolide drug-resistant gene ermB.

The processing technology comprises the following steps: stirring and mixing beta-cyclodextrin and purified water in a stirring tank according to a ratio of 1: 1.25 to prepare a saturated aqueous solution, mixing azithromycin and absolute ethyl alcohol according to a ratio of 1: 1.5 to completely dissolve the azithromycin, and granulating the azithromycin and the absolute ethyl alcohol to prepare the azithromycin dry suspension. The preparation method comprises the following steps: adding dissolved azithromycin into a beta-cyclodextrin saturated water solution, uniformly mixing through a wet mixing granulator to prepare a suitable soft material, carrying out boiling drying, granulating, totally mixing, carrying out inner packaging and outer packaging by using a composite film, and finally warehousing. According to the characteristic that the effective components are bitter in taste, the beta-cyclodextrin has a unique annular structure, the interior of a molecular cavity of the beta-cyclodextrin is hydrophobic, the exterior of the beta-cyclodextrin is hydrophilic, various guest molecules can be included in the cavity through intermolecular acting force to form an inclusion compound, the bitter effective components are included in a framework of the beta-cyclodextrin, and the taste is improved.

The present invention discloses a novel hydrogel-based BMSCs-loaded azithromycin formulation, its preparation method, and application. The novel hydrogel-based BMSCs-loaded azithromycin formulation comprises albumin-azithromycin-nanoparticles sequentially encapsulated by rat bone marrow mesenchymal stem cells and chitosan hydrogel; the mass ratio of the albumin-azithromycin-nanoparticles, rat bone marrow mesenchymal stem cells, and chitosan hydrogel is 1:1-2:1-2; the albumin-azithromycin-nanoparticles are nanoparticles formed by encapsulating azithromycin in albumin, and the mass ratio of the azithromycin to the albumin is 1:4-5. The present invention successfully prepared a novel formulation, BMSCs-TAT-AZM-NPs@Gel; this system not only exhibits anti-inflammatory, antioxidant, and promotes damaged tissue repair; at the same time, the novel formulation also reduces the toxic and side effects of AZM, improves the safety of the drug, and provides a new approach for the treatment of spinal cord injury.

A medicated eyelid cleansing composition comprising a medicated scrub composition and an eyelid cleansing composition. The medicated scrub composition has one or more antibacterial and anti-inflammatory agents, including azithromycin and diclofenac sodium or dexamethasone phosphate. The medicated scrub composition can further include a combination of metronidazole and ivermectin. The composition is optimized for physiological compatibility and can be combined with a suitable substrate for use as a medicated eyelid cleanser.

This application relates to the field of biotechnology, and particularly to primer pairs, primer-probe compositions, PCR premixes, kits, and methods for detecting multiple respiratory pathogens. Nucleic acid sequences are shown in primer pairs as indicated by SEQ ID NO: 1-2, 4-5, 7-8, 10-11, 13-14, 16-17, 19-20, 22-23, 25-26, 28-29, 31-32, 34-35, 37-38, and 40-41. For target respiratory pathogens, this application designs specific amplification primer pairs, paired with suitable probes, enabling the simultaneous detection of eight targets. Furthermore, the detection process avoids interference from heme, trimethoprim, sulfamethoxazole, amphotericin B, itraconazole, fluconazole, azithromycin, adrenaline, and lidocaine hydrochloride in the test sample. It exhibits good anti-interference properties and shows no cross-reactivity with *Rhodococcus equi*, *Candida tropicalis*, and *Candida krusei*.

The application belongs to the technical field of antibacterial infection materials, and particularly relates to preparation and application of a biomimetic mineralization nanoparticle. x S y / AZM, which is obtained by fixing glucose oxidase (GOx) in FexSy nanoparticles hybridized with azithromycin (AZM) through a biomimetic mineralization strategy, and the nanoparticle GOx@Fe x S y / AZM serves as a therapeutic drug to catalyze a large amount of active oxygen free radicals (ROS) to improve inflammatory response in order to rapidly kill infectious microorganisms in the early stage of bacterial infection of a wound surface; and in the subsequent healing period, H2S released by the material and AZM will jointly promote the polarization of macrophages to M2 macrophages of a repair type to effectively mediate the tissue repair after a high inflammatory response, so that the ordered treatment of a high blood sugar infection wound surface is achieved.

The application discloses a molecular imprinting polymer electrocatalytic polar plate and a preparation method and application thereof, and the preparation method comprises the following steps: cleaning an electrode plate; stirring a benzene[1,2-B:4,5-B']dithiophene-4,8-dione, 3-boronic acid thiophene, azithromycin, 3,3'-bithiophene and tetrabutylammonium perchlorate acetonitrile solution to obtain a polymerization solution; taking a graphite plate as a working electrode and a counter electrode, and taking a non-aqueous Ag + The electrode is a reference electrode, the electro-polymerization is completed in the polymerization solution, and a MIP (PBth-BQ) molecular imprinting catalytic electrode is obtained; the MIP (PBth-BQ) molecular imprinting catalytic electrode is taken as a working electrode, the graphite sheet is taken as a counter electrode, saturated mercury is taken as a reference electrode, constant-temperature water bath stirring is carried out, the template is removed, and cleaning is carried out. The electrocatalytic polar plate has holes on the surface, the azithromycin is wrapped first and then removed, the adsorption effect is better, the selectivity is high, the adsorption and electrocatalysis are synergistically combined, and the removal effect is good.

The invention provides azithromycin water-free swallowing granules and a preparation method thereof, and belongs to the field of pharmaceutical preparations. The azithromycin water-free swallowing granules are prepared by mixing medicine-containing taste-masking pellets and taste-modifying granules. The medicine-containing taste-masking pellet sequentially comprises a medicine-containing pellet core, an isolating layer and a taste-masking layer from inside to outside, and the medicine-containing pellet core is prepared through a centrifugal pelleting process. The technical problem to be solved is that the azithromycin water-free swallowing granule can realize water-free rapid swallowing, keeps good taste in the whole process, remarkably improves medication convenience and patient compliance, and is particularly suitable for children and other groups with difficulty in swallowing.

The invention relates to an azithromycin hapten, an azithromycin artificial antigen and application thereof. The azithromycin A is used as an initial raw material, an active arm is introduced from a secondary amine terminal, all hydroxyl and tertiary amine structures of an azithromycin drug are completely reserved, the prepared hapten has a relatively good space structure, the electron cloud density of the hapten is basically consistent with that of an original drug, and the immunogenicity of the antigen is improved; the prepared azithromycin artificial antigen and the monoclonal antibody are high in specificity when being used for ELISA (enzyme-linked immunosorbent assay) detection, and the IC50 value is 0.03 g / L; a further established colloidal gold immunochromatography test strip can rapidly and conveniently realize qualitative detection of azithromycin, the sensitivity of the azithromycin in a standard solution is 0.5 g / kg, and the detection sensitivity of the azithromycin in a sample can reach 0.5 g / kg.

The invention relates to the technical field of traditional Chinese medicines, and particularly discloses a navel therapy composition and a navel therapy preparation for preventing and treating abdominal pain caused by intravenous drip of azithromycin in children and a preparation method of the navel therapy composition and the navel therapy preparation. The technical key points are as follows: the fructus evodiae and the dysentery are combined according to a specific weight ratio, and are matched with pharmaceutic adjuvants such as a transdermal enhancer and an excipient to prepare special navel therapy dosage forms such as pills, cakes, patches and the like. According to the composition, by utilizing the characteristics that the Shenque acupoint (navel) epidermal cuticle is thin, the barrier function is weak, blood vessels are rich, and medicines are easy to disperse and absorb, adverse reactions such as gastrointestinal spasmodic pain, nausea and vomiting and the like caused by intravenous drip of azithromycin in children are effectively relieved through an administration mode of external application. Through clinical verification, the umbilical therapy preparation can remarkably reduce the incidence rate and severity score of stomachache, vomiting and diarrhea, and remarkably improve the treatment compliance of child patients.

The application discloses a synergistic bactericidal composition, comprising the following components: a toona sinensis extract: 16-2048 mu g / mL; a macrolide antibiotic: 0.0625-4096 mu g / mL; the bacteria are staphylococcus aureus or methicillin-resistant staphylococcus aureus, and the macrolide antibiotic is erythromycin or azithromycin. The application further discloses a use of the synergistic bactericidal composition in preparation of a medicine for treating skin and soft tissue infections. The composition provided by the application can convert the traditional macrolide antibiotics such as erythromycin and azithromycin which only have a bacteriostatic effect into a preparation which has clear bactericidal activity on staphylococcus aureus and drug-resistant strains thereof. After the toona sinensis extract is combined with the antibiotic, a synergistic effect is exhibited, and the concentration of the toona sinensis extract and the antibiotic required when the toona sinensis extract and the antibiotic are used alone can be greatly reduced.

The present invention relates to a macrolide compound, and a preparation method therefor and the use thereof. Specifically disclosed is a compound as shown in formula I or a pharmaceutically acceptable salt thereof. The compound of the present invention exhibits a significant antibacterial activity, comprising the antibacterial activity against bacteria resistant to macrolide drugs such as azithromycin. The compound described herein has a low hepatotoxicity and superior safety compared to other macrolide compounds. The compound can be used for infectious diseases, etc.

The present invention relates to an aminopyridone macrolide compound and the use thereof. Specifically disclosed is a compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound of the present invention exhibits antibacterial, antimycoplasmal or antichlamydial activity, and can be used for preventing and / or treating related diseases caused by bacteria, mycoplasmas or chlamydias. Further, the compound of the present application can achieve an antibacterial activity comparable to or better than that of azithromycin or solithromycin at a lower dosage. Still further, the compound of the present application exhibits a superior antibacterial effect on Gram-positive bacteria. Even further, the compound of the present application exhibits a better inhibitory activity against mycoplasmas and a lower hepatotoxicity.

The invention provides application of synergy of ethyl ferulate and antibiotics in preparation of a synergistic antibacterial drug for escherichia coli O157: H7, and belongs to the technical field of antibacterial drugs. The invention firstly provides an application of ethyl ferulate in preparation of a medicine for resisting a biofilm inhibitor, and provides an application of ethyl ferulate and antibiotics in preparation of a synergistic antibacterial medicine for escherichia coli O157: H7 based on the application of ethyl ferulate and antibiotics in preparation of a synergistic antibacterial medicine for escherichia coli O157: H7. The invention proves that the ethyl ferulate has a remarkable inhibition effect on the formation of an escherichia coli O157: H7 biofilm for the first time. The invention also proves that when the ethyl ferulate is combined with the existing antibiotics (fosfomycin sodium, cefquinome, gentamicin, tetracycline and azithromycin), a synergistic effect can be generated. Therefore, the ethyl ferulate is thought to have dual effects of resisting the biofilm and synergistically resisting bacteria on the escherichia coli.

An aseptically prepared pharmaceutically acceptable azithromycin premix formulation has a pH value of 5.5 to 7.5, preferably 6.0 to 7.0, more preferably 6.3 to 7.0, even more preferably 6.3 to 6.7, for example about 6.5. Preferred embodiments of the aseptically prepared pharmaceutically acceptable azithromycin premix formulation contain azithromycin, a buffering agent, water and optionally a tonicity adjusting agent and are stable for one month, three months, six months, nine months, twelve months, fifteen months, eighteen months or even twenty-four months, during storage at refrigerated temperatures, such as about 5 °C, even without any additional components beyond the azithromycin, the buffering agent, and the optional tonicity adjusting agent in the premix formulation. The pharmaceutically acceptable azithromycin premix formulation may be aseptically filled into a container, preferably a glass or flexible container, to form a sterile pharmaceutical azithromycin premix product which does not undergo terminal sterilization. The azithromycin premix product can be a single use premix which is a sterile, stable and ready-to-use aqueous solution for parenteral administration, for example intravenous (IV) administration such as IV infusion, and requires no dilution prior to parenteral administration.

The invention discloses an azithromycin fumarate sustained-release tablet and a preparation method thereof, and particularly relates to the technical field of pharmaceutical preparations, and the sustained-release tablet comprises the following components based on 100% of the total mass of the sustained-release tablet: 30-50% of azithromycin fumarate, 5-20% of a wax retardant material, 20-40% of a high polymer material sustained-release matrix, 10-20% of a filler, 5-10% of a sweetener, 0.5-5% of a lubricating flow aid, and the balance of an adhesive. According to the invention, the dissolution and release degree of the medicine can be reduced, the peak concentration of the medicine is reduced, the peak valley fluctuation of the blood concentration is reduced, the adverse reaction of the medicine is slowed down, the effective blood concentration duration is prolonged, the clinical treatment effect of the medicine is improved, and the compliance, convenience and compliance of patient medication are also improved; the generation of drug resistance is reduced to the greatest extent.

The invention relates to a pyridone macrolide compound and application thereof. Specifically disclosed is a compound represented by formula I-1 or I-1 'or a pharmaceutically acceptable salt thereof. The compound disclosed by the invention has the activity of resisting bacteria, mycoplasma or chlamydia, and can be used for preventing and / or treating related diseases caused by bacteria, mycoplasma or chlamydia; furthermore, the antibacterial activity equivalent to or better than that of azithromycin or solificin can be achieved by using a lower dosage of the compound provided by the invention; furthermore, the compound provided by the invention has a better antibacterial effect on gram-positive bacteria; furthermore, the compound provided by the invention has better inhibitory activity and lower hepatotoxicity to mycoplasma.

The invention provides a method for detecting hydroxylamine hydrochloride in azithromycin, and belongs to the technical field of pharmaceutical analysis. The detection method adopts ultraviolet detector type high performance liquid chromatography for detection, and specifically comprises the following steps: (1) preparation of a test solution: taking to-be-detected azithromycin and anhydrous sodium acetate, dissolving the azithromycin and anhydrous sodium acetate with an alcohol organic solvent, and then adding acetic acid and benzaldehyde for derivatization to obtain the test solution; and (2) injecting the test solution into a high performance liquid chromatograph for detection, and recording a chromatogram. According to the detection method disclosed by the invention, quantitative detection of hydroxylamine hydrochloride in azithromycin can be realized by adopting an ultraviolet detector type high performance liquid chromatograph, the responsivity is high, and the universality is good. Besides, the detection method is good in separation effect on hydroxylamine hydrochloride in azithromycin, good in detection specificity, high in sensitivity and low in detection cost, so that the detection method is very suitable for quantitative detection of hydroxylamine hydrochloride in azithromycin and has a good application prospect.

The invention discloses a method for detecting the concentration of eight second-line antituberculous drugs based on HPLC-MS / MS. The eight second-line antituberculous drugs are divided into two groups for detection, one group takes levofloxacin as an internal standard substance, and an internal standard stock solution is prepared; the method comprises the following steps: detecting by taking standard substances of levofloxacin, ciprofloxacin and gatifloxacin as target substances; and in the other group, albendamide, deramanib, pritomanib, clarithromycin and azithromycin are used as target objects for detection. According to the method, the detection time is short, only 5 min is needed, and the detection time is saved; meanwhile, according to the method disclosed by the invention, the consumption of an organic solvent is reduced, so that the pollution to the environment is reduced, and the method has the characteristics of high accuracy and good precision, and provides the fastest and effective basis for clinical treatment.

The present disclosure is directed to liquid azithromycin formulations, methods for the preparation of the same, and uses thereof.

The antimicrobial composition comprises a mixture or a reaction product of at least turmeric extract (TME), japonica extract (SJE) and Azithromycin (AZM), wherein the ratio of the mass of turmeric extract (TME) to the mass of japonica extract (SJE), mT\n.: msjE is in the range from 1 : 10 to 10: 1, and wherein the ratio of the sum of the masses of turmeric extract (TME) and japonica extract (SJE) to the mass of Azithromycin (AZM), (mTME + mSJE) : mAZM is in the range from 1 : 10 to 10: 1. The composition has an excellent antimicrobial effect. It can be embedded in products or placed on their surfaces and prevents or impedes the settling of microorganisms.

The invention discloses a preparation method of azithromycin for injection, which comprises the following steps: respectively dissolving anhydrous citric acid and sodium hydroxide in water for injection to form an acidic solution and an alkaline solution; adding the acidic solution into the alkaline solution in a gradient manner under the protection of inert gas to form a buffer mixed solution with the pH value range of 6.5-6.7; mixing an azithromycin raw material with the buffer mixed solution to form a liquid medicine; carrying out multi-stage filtration treatment on the liquid medicine; filling the filtered liquid medicine into a penicillin bottle; and carrying out freeze drying treatment on the penicillin bottle filled with the liquid medicine. The PH value of the buffer mixed solution is accurately stabilized at 6.5-6.7 through gradient mixing, generation of a local over-acid or over-alkali area is avoided, and then the probability of the solution rate after the azithromycin and the buffer mixed solution are mixed subsequently is reduced. And the liquid medicine is subjected to multi-stage filtration, so that the microorganism retention rate is improved, and the endotoxin residual quantity is reduced.

1. The name of the design product: packaging box (azithromycin tablets). 2. The use of the design product: storage and storage of medicines. 3. The design features of the design product: in the pattern. 4. The picture or photo that best indicates the design features: front view.

Formulations and methods for treatment of coccidia infections in an animal. The method includes obtaining a formulation of Statin (e.g., Atorvastatin), Indomethacin, Doxycycline, Cimetidine, Lincomycin, Sulfamethoxazole, Trimethoprim, Diclazuril, Salinomycin, Budesonide, Amprolium, Azithromycin, and / or any combination thereof; and providing the formulation to an animal.

The application provides an azithromycin composition for injection and a preparation process thereof, and relates to the field of pharmaceutical preparations.The azithromycin composition for injection provided by the application is composed of azithromycin, citric acid and sodium hydroxide.The preparation process comprises the following steps: dissolving azithromycin, citric acid and sodium hydroxide in water for injection to obtain a medicinal solution; and vacuum freeze-drying the medicinal solution to obtain the azithromycin composition for injection; the vacuum freeze-drying process comprises the following steps in sequence: pre-freezing, sublimation drying and desorption drying; the application has the advantages that the prescription and accessories are few in types, the dosages are reasonable, the liquid preparation process is more optimal, the raw material dissolving time is short, the medicinal solution is stable, and no impurities are brought in by using activated carbon; the freeze-drying process cycle is short, the appearance of the freeze-dried product is beautiful, the re-dissolving time is short, the re-dissolved solution is more optimal in clarity, and the freeze-dried product has excellent stability, so that the clinical drug safety of the product is fundamentally ensured.